Adicet Bio, Inc.

NASDAQ:ACET

Biotechnology

Healthcare
$5.53 +0.25%

+$0.02 today

Market cap
$51.70M
Beta
1.57
P/E (TTM)
-0.8
EPS (TTM)
-$10.13
52W Low $6.01High $17.44

Volume 0.15M

Average 0.12M

Returns on capital

Adicet Bio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-73.4%

avg -28.8%

ROIC

-70.2%

avg -33.1%

ROA

-60.7%

avg -31.3%

Analysis

ROA is currently the strongest return metric at -60.7% versus its period average of -31.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Chen Schor

Chief Executive Officer, President & DirectorUSD 953.67K5455.00K0.59%

Blake Aftab

Senior Vice President & Chief Scientific OfficerUSD 731.12K4555.00K0.59%

Julie Maltzman

Chief Medical OfficerUSD 622.2K58——

Brian Nicholas Harvey

Chief Financial OfficerUSD 611.14K6543.36K0.46%

Donald Healey

Chief Technology OfficerUSD 606.34K64——

Lloyd Klickstein

Interim Chief Medical Officer & DirectorUSD 44K6918.30K0.20%

Amy Locke

Chief Human Resource Officer————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$1.60M

Sells

4

$674,847.06

Net Transaction Value

+$929,087.07

Net buying

Most Active

ORBIMED ADVISORS LLC

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 8, 26

ORBIMED ADVISORS LLC

Indirect

Sell$263.5K
Apr 8, 26

ORBIMED ADVISORS LLC

Indirect

Sell$204.6K
Apr 7, 26

ORBIMED ADVISORS LLC

Indirect

Sell$191.5K
Apr 7, 26

ORBIMED ADVISORS LLC

Indirect

Sell$15.3K
Feb 20, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Buy$543.4K
Feb 19, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Buy$535.5K
Feb 18, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Buy$525K

Summary

Insiders reported 3 buys worth $1.60M and 4 sells worth $674,847.06 over the last 12 months. That adds up to net buying of $929,087.07. ORBIMED ADVISORS LLC was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Adicet Bio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ACET's management, answered from reported figures.

Who manages ACET?

Adicet Bio, Inc. (ACET) lists 7 active executives. The top listed executive is Chen Schor, Chief Executive Officer, President & Director.

Are ACET insiders buying or selling?

Recent insider activity shows net buying of $3.53M.